| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_23836c501a0d7d5c51f5fc63b22348b3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_59f28e4f3a27d5e62c219379e19acf1b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1721d75f5bf603447ec5a26b5c1c0be0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c2f4176a88df0463c729e736cdbab2c8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b74632e43bf686718613ddc2531a5751 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-9645 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M1-3675
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-86
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-4846 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61M1-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-86 |
| filingDate |
1997-05-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3bd5bc692dca07748c57febdb9cf8372
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8d22113b06110ba724a78e336a9d5bca
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fa3dca4fea6c696c6fa21fb6fbca41a6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b65d7ef44a71bf9382db8402d95019b7 |
| publicationDate |
1997-11-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-9742900-A1 |
| titleOfInvention |
Method for inhibiting thrombosis in a patient whose blood is subjected to extracorporeal circulation |
| abstract |
This invention provides a method for inhibiting thrombosis in a patient whose blood is subjected to extracorporeal blood circulation which comprises contacting the extracorporeal circulating blood with a Factor IXa compound in an amount effective to inhibit thrombosis in the patient. The Factor IXa compound may include an active site-blocked Factor IXa compound or Glu-Gly-Arg chloromethyl ketone-inactivated human factor IXa compound. This invention also provides that the effective amount may be from about 0.1 νg/ml plasma to about 250 νg/ml plasma or from about 0.5 νg/ml plasma to about 25 νg/ml plasma. The patient may be subjected to extracorporeal blood circulation during transplant surgery or cardiopulmonary bypass surgery. This invention further provides for a pharmaceutical composition which includes an effective amount of a Factor IXa compound and a pharmaceutically acceptable carrier. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11517631-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2004102202-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101154246-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8128963-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2004239468-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11344608-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10413598-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10842885-B2 |
| priorityDate |
1996-05-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |